Capricor Therapeutics and CureDuchenne hosted a webinar on June 19, 2015. The presentation discussed the HOPE-DUCHENNE Trial. The U.S. Food and Drug Adminstration has cleared Capricor’s Investigational New Drug Application for the clinical development of CAP-1002 for the treatment of patients with Duchenne muscular dystrophy. CAP-1002 is Capricor’s allogeneic, cardiospehere-derived cell therapy already in clinical development for the treatment of heart disease. The webinar discussed plans for the trial.
Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.